These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 30377572)

  • 1. PD-L1 blockade enhances anti-tumor efficacy of NK cells.
    Oyer JL; Gitto SB; Altomare DA; Copik AJ
    Oncoimmunology; 2018; 7(11):e1509819. PubMed ID: 30377572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryopreserved PM21-Particle-Expanded Natural Killer Cells Maintain Cytotoxicity and Effector Functions
    Oyer JL; Croom-Perez TJ; Dieffenthaller TA; Robles-Carillo LD; Gitto SB; Altomare DA; Copik AJ
    Front Immunol; 2022; 13():861681. PubMed ID: 35464440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types.
    Hicks KC; Fantini M; Donahue RN; Schwab A; Knudson KM; Tritsch SR; Jochems C; Clavijo PE; Allen CT; Hodge JW; Tsang KY; Schlom J; Gameiro SR
    Oncoimmunology; 2018; 7(11):e1466018. PubMed ID: 30377559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers.
    Moore EC; Cash HA; Caruso AM; Uppaluri R; Hodge JW; Van Waes C; Allen CT
    Cancer Immunol Res; 2016 Jul; 4(7):611-20. PubMed ID: 27076449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
    Hsu J; Hodgins JJ; Marathe M; Nicolai CJ; Bourgeois-Daigneault MC; Trevino TN; Azimi CS; Scheer AK; Randolph HE; Thompson TW; Zhang L; Iannello A; Mathur N; Jardine KE; Kirn GA; Bell JC; McBurney MW; Raulet DH; Ardolino M
    J Clin Invest; 2018 Oct; 128(10):4654-4668. PubMed ID: 30198904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression.
    Bellucci R; Martin A; Bommarito D; Wang K; Hansen SH; Freeman GJ; Ritz J
    Oncoimmunology; 2015 Jun; 4(6):e1008824. PubMed ID: 26155422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIGIT Expression on Activated NK Cells Correlates with Greater Anti-Tumor Activity but Promotes Functional Decline upon Lung Cancer Exposure: Implications for Adoptive Cell Therapy and TIGIT-Targeted Therapies.
    Hasan MF; Croom-Perez TJ; Oyer JL; Dieffenthaller TA; Robles-Carrillo LD; Eloriaga JE; Kumar S; Andersen BW; Copik AJ
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 Mediates Dysfunction in Activated PD-1
    Concha-Benavente F; Kansy B; Moskovitz J; Moy J; Chandran U; Ferris RL
    Cancer Immunol Res; 2018 Dec; 6(12):1548-1560. PubMed ID: 30282672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy.
    Shevtsov M; Sato H; Multhoff G; Shibata A
    Front Oncol; 2019; 9():156. PubMed ID: 30941308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.
    Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M
    Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases.
    Dhupkar P; Gordon N; Stewart J; Kleinerman ES
    Cancer Med; 2018 Jun; 7(6):2654-2664. PubMed ID: 29733528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy.
    Cichocki F; Bjordahl R; Gaidarova S; Mahmood S; Abujarour R; Wang H; Tuininga K; Felices M; Davis ZB; Bendzick L; Clarke R; Stokely L; Rogers P; Ge M; Robinson M; Rezner B; Robbins DL; Lee TT; Kaufman DS; Blazar BR; Valamehr B; Miller JS
    Sci Transl Med; 2020 Nov; 12(568):. PubMed ID: 33148626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
    Boyerinas B; Jochems C; Fantini M; Heery CR; Gulley JL; Tsang KY; Schlom J
    Cancer Immunol Res; 2015 Oct; 3(10):1148-1157. PubMed ID: 26014098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.